Cardinal Health Korea Ltd.
Cordis Corporation, a Cardinal Health company, has pioneered less invasive treatments for vascular disease. Technological innovation and a deep understanding of the medical marketplace and the needs of patients have made Cordis the world's leading developer and manufacturer
Satellite Symposium
| Lunchtime Activities |
| Reengineering the Art of EVAR : Optimal AAA Device for Asian Patients- from Clinical Evidence to Routine Practice of InCraft |
| Organized by CVRF and Supported by Educational Grant from Cardinal Health Korea Ltd. |
Wednesday, April 26
12:45 PM - 1:45 PM
Room 2A, Level 3 |
| Moderator(s): Donghoon Choi |
| Panelist(s): Min-Ku Chon, Dong-Kie Kim, Sangmin Kim, Jung-Hee Lee, Ha Wook Park, Sanghoon Shin |
|
| 12:45 PM |
Opening Remark |
| 12:46 PM |
Challenging the Limit of Endovascular Abdominal Aortic Aneurysm Repair |
| 1:00 PM |
Clinical Evidence from INSPIRATION Trial |
| 1:15 PM |
Clinical Benefit of Ultra-low Profile for Asian Patients |
| 1:30 PM |
Discussion
|
| 1:44 PM |
Closing Remark |
| Lunchtime Activities |
| The Moment of Truths : High Bleeding Risk Patients: from Clinical Evidence to Routine Practice of BioFreedom™ |
| Organized by CVRF and Supported by Educational Grant from Cardinal Health Korea Ltd. |
Thursday, April 27
12:45 PM - 1:45 PM
Valve Theater, Level 1 |
| Moderator(s): Yangsoo Jang |
| Panelist(s): Atsushi Hirohata, Young Joon Hong, Kentaro Jujo, Weon Kim, Jung-Hee Lee, Shimpei Nakatani |
|
| 12:45 PM |
Opening Remark |
| 12:46 PM |
LEADERS Free Two Years Follow-up |
| 1:00 PM |
Who Is Going to Bleed? |
| 1:15 PM |
Clinical Practice of BioFreedom™ and Short Duration DAPT for High Bleeding Risk Patients |
| 1:30 PM |
Discussion
|
| 1:44 PM |
Closing Remark |
